Author: Houng, Huo-Shu H; Norwood, David; Ludwig, George V; Sun, Wellington; Lin, Minta; Vaughn, David W
Title: Development and evaluation of an efficient 3′-noncoding region based SARS coronavirus (SARS-CoV) RT-PCR assay for detection of SARS-CoV infections Cord-id: o9glkhyv Document date: 2004_9_1
ID: o9glkhyv
Snippet: The severe acute respiratory syndrome (SARS) epidemic originating from China in 2002 was caused by a previously uncharacterized coronavirus that could be identified by specific RT-PCR amplification. Efforts to control future SARS outbreaks depend on the accurate and early identification of SARS-CoV infected patients. A real-time fluorogenic RT-PCR assay based on the 3′-noncoding region (3′-NCR) of SARS-CoV genome was developed as a quantitative SARS diagnostic tool. The ideal amplification e
Document: The severe acute respiratory syndrome (SARS) epidemic originating from China in 2002 was caused by a previously uncharacterized coronavirus that could be identified by specific RT-PCR amplification. Efforts to control future SARS outbreaks depend on the accurate and early identification of SARS-CoV infected patients. A real-time fluorogenic RT-PCR assay based on the 3′-noncoding region (3′-NCR) of SARS-CoV genome was developed as a quantitative SARS diagnostic tool. The ideal amplification efficiency of a sensitive SARS-CoV RT-PCR assay should yield an E value (PCR product concentration increase per amplification cycle) equal to 2.0. It was demonstrated that the 3′-NCR SARS-CoV based RT-PCR reactions could be formulated to reach excellent E values of 1.81, or 91% amplification efficacy. The SARS-CoV cDNA preparations derived from viral RNA extract and the cloned recombinant plasmid both exhibit the identical amplification characteristics, i.e. amplification efficacy using the same PCR formulation developed in this study. The viral genomic copy (or genomic equivalences, GE) per infectious unit (GE/pfu) of SARS-CoV used in this study was also established to be approximate 1200–1600:1. The assay’s detection sensitivity could reach 0.005 pfu or 6–8 GE per assay. It was preliminarily demonstrated that the assay could efficiently detect SARS-CoV from clinical specimens of SARS probable and suspected patients identified in Taiwan. The 3′-NCR based SARS-CoV assay demonstrated 100% diagnostic specificity testing samples of patients with acute respiratory disease from a non-SARS epidemic region.
Search related documents:
Co phrase search for related documents- accumulation show and acute respiratory syndrome: 1, 2, 3
- accumulation show and acute sars respiratory syndrome: 1, 2, 3
- accurately sars cov identify and acute respiratory syndrome: 1, 2, 3, 4
- accurately sars cov identify and acute sars respiratory syndrome: 1, 2, 3, 4
- acute respiratory disease and adenovirus cause: 1, 2, 3, 4, 5
- acute respiratory disease and low assay detection limit: 1
- acute respiratory disease and low concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute respiratory disease and low copy number: 1
- acute respiratory syndrome and adenovirus cause: 1, 2, 3, 4
- acute respiratory syndrome and log dilution: 1, 2, 3, 4
- acute respiratory syndrome and low assay detection limit: 1
- acute respiratory syndrome and low concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and low copy number: 1, 2, 3
- acute sars respiratory syndrome and log dilution: 1, 2
- acute sars respiratory syndrome and low assay detection limit: 1
- acute sars respiratory syndrome and low concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute sars respiratory syndrome and low copy number: 1, 2
Co phrase search for related documents, hyperlinks ordered by date